Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease

Abstract EN

Prevention of bone fractures is one goal of therapy for patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), as indicated by the Kidney Disease: Improving Global Outcomes guidelines.

CKD patients, including those on hemodialysis, are at higher risk for fractures and fracture-related death compared to people with normal kidney function.

However, few clinicians focus on this issue as it is very difficult to estimate bone fragility.

Additionally, uremia-related bone fragility has a more complicated pathological process compared to osteoporosis.

There are many uremia-associated factors that contribute to bone fragility, including severe secondary hyperparathyroidism, skeletal resistance to parathyroid hormone, and bone mineralization disorders.

Uremia also aggravates bone volume loss, disarranges microarchitecture, and increases the deterioration of material properties of bone through abnormal bone cells or excess oxidative stress.

In this review, we outline the prevalence of fractures, the interaction of CKD-MBD with osteoporosis in CKD patients, and discuss possible factors that exacerbate the mechanical properties of bone.